Biodegradable intravitreal tyrosine kinase implants

US10076492B2 · kind B2 · utility

Assignee

• Allergan, Inc. · US

Inventors

• Jeffrey L. Edelman · Irvine, US
• Patrick M. Hughes · Aliso Viejo, US
• Thomas C. Malone · Irvine, US
• Gerald W. DeVries · San Clemente, US
• Joan-En Chang-Lin · Tustin, US
• Jane-Guo Shiah · Irvine, US
• Thierry Nivaggioli · San Francisco, US
• Lon T. Spada · Walnut, US
• Wendy M. Blanda · Tustin, US

Key dates

• Filing date: Jan 11, 2016
• Grant date: Sep 18, 2018
• Expiry date: Jan 11, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.